-
1 month ago | 
bmj.com | Sonia Anand |Jackie Bosch |Roxana Mehran |Shamir R. Mehta
Sonia S Anand, Canada research chair in ethnic diversity and cardiovascular disease134, Jackie Bosch, professor13 5, Roxana Mehran, professor6, Shamir R Mehta, professor3 4, Manesh R Patel, professor7 1Chanchlani Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada 2Mary Heersink School of Global Health and Social Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada 3Population Health Research Institute, Hamilton Health...
-
Oct 16, 2024 | 
dialnet.unirioja.es | Pabla Cataldo |Roxana Mehran
yes we can!
-
May 22, 2024 | 
icrjournal.com | Ole De Backer |Roxana Mehran |Ling Tao
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).
-
May 22, 2024 | 
icrjournal.com | Ling Tao |Roxana Mehran |Ole De Backer
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial. Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT followed by 5-month Ticagrelor monotherapy in patients with acute coronary syndromes with DCB.
-
May 21, 2024 | 
icrjournal.com | Roxana Mehran |Ling Tao |Ole De Backer
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) joins us to discuss the findings from an ancillary analysis of the SMART trial (NCT04722250). The SMART trial is a prospective, multi-center, randomized controlled study that aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and severe symptomatic aortic stenosis.
-
May 21, 2024 | 
icrjournal.com | Roxana Mehran |Bernardo Cortese |Ling Tao |Ole De Backer
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024. The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary intervention (PCI).
-
May 20, 2024 | 
icrjournal.com | Roxana Mehran |Bernardo Cortese |Joost Daemen
Video EuroPCR 2024: 4 Trials That Will Change My Practice with Dr Bernardo Cortese Published: 20 May 2024 Views: 143 Likes: 0 Average (ratings) No ratings EuroPCR 2024 - We are joined by Dr Bernardo Cortese (Ospedale Fate bene Fratelli, IT) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.
-
May 15, 2024 | 
healio.com | Erik Swain |Richard Smith |Roxana Mehran
Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:In women with small aortic annuli who underwent TAVR, a self-expanding valve conferred better 1-year hemodynamic outcomes vs. a balloon-expandable valve.
-
Mar 20, 2024 | 
nature.com | Azita H. Talasaz |Parham Sadeghipour |John Eikelboom |Deborah M. Siegal |Manuel Monreal |David Jimenez | +8 more
AbstractBalancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities.
-
Mar 20, 2024 | nature.com | Azita H. Talasaz |Parham Sadeghipour |John Eikelboom |Deborah M. Siegal |Manuel Monreal |David Jimenez | +8 more
AbstractBalancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities.
